S&P 500   4,997.81 (-0.27%)
DOW   38,091.03 (+0.84%)
QQQ   417.03 (-1.51%)
AAPL   165.04 (-1.20%)
MSFT   400.12 (-1.03%)
META   484.70 (-3.41%)
GOOGL   154.17 (-1.18%)
AMZN   174.99 (-2.36%)
TSLA   149.15 (-0.52%)
NVDA   804.98 (-4.93%)
AMD   149.23 (-3.77%)
NIO   3.84 (-4.00%)
BABA   68.92 (+0.06%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   106.72 (-4.65%)
GE   149.39 (-2.32%)
CGC   8.17 (+4.34%)
DIS   112.17 (-0.23%)
AMC   3.26 (+11.64%)
PFE   25.80 (+1.61%)
PYPL   62.14 (+0.06%)
XOM   119.98 (+1.23%)
S&P 500   4,997.81 (-0.27%)
DOW   38,091.03 (+0.84%)
QQQ   417.03 (-1.51%)
AAPL   165.04 (-1.20%)
MSFT   400.12 (-1.03%)
META   484.70 (-3.41%)
GOOGL   154.17 (-1.18%)
AMZN   174.99 (-2.36%)
TSLA   149.15 (-0.52%)
NVDA   804.98 (-4.93%)
AMD   149.23 (-3.77%)
NIO   3.84 (-4.00%)
BABA   68.92 (+0.06%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   106.72 (-4.65%)
GE   149.39 (-2.32%)
CGC   8.17 (+4.34%)
DIS   112.17 (-0.23%)
AMC   3.26 (+11.64%)
PFE   25.80 (+1.61%)
PYPL   62.14 (+0.06%)
XOM   119.98 (+1.23%)
S&P 500   4,997.81 (-0.27%)
DOW   38,091.03 (+0.84%)
QQQ   417.03 (-1.51%)
AAPL   165.04 (-1.20%)
MSFT   400.12 (-1.03%)
META   484.70 (-3.41%)
GOOGL   154.17 (-1.18%)
AMZN   174.99 (-2.36%)
TSLA   149.15 (-0.52%)
NVDA   804.98 (-4.93%)
AMD   149.23 (-3.77%)
NIO   3.84 (-4.00%)
BABA   68.92 (+0.06%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   106.72 (-4.65%)
GE   149.39 (-2.32%)
CGC   8.17 (+4.34%)
DIS   112.17 (-0.23%)
AMC   3.26 (+11.64%)
PFE   25.80 (+1.61%)
PYPL   62.14 (+0.06%)
XOM   119.98 (+1.23%)
S&P 500   4,997.81 (-0.27%)
DOW   38,091.03 (+0.84%)
QQQ   417.03 (-1.51%)
AAPL   165.04 (-1.20%)
MSFT   400.12 (-1.03%)
META   484.70 (-3.41%)
GOOGL   154.17 (-1.18%)
AMZN   174.99 (-2.36%)
TSLA   149.15 (-0.52%)
NVDA   804.98 (-4.93%)
AMD   149.23 (-3.77%)
NIO   3.84 (-4.00%)
BABA   68.92 (+0.06%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   106.72 (-4.65%)
GE   149.39 (-2.32%)
CGC   8.17 (+4.34%)
DIS   112.17 (-0.23%)
AMC   3.26 (+11.64%)
PFE   25.80 (+1.61%)
PYPL   62.14 (+0.06%)
XOM   119.98 (+1.23%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IsoPlexis Co. stock logo
ISO
IsoPlexis
$0.76
$0.86
$0.60
$5.10
$30.28M1.3268,375 shsN/A
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
$0.27
$0.21
$0.14
$1.07
$9.30M-0.1161,255 shs37,260 shs
Precipio, Inc. stock logo
PRPO
Precipio
$6.20
-7.6%
$6.41
$4.75
$14.80
$8.87M1.616,366 shs1,603 shs
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$8.94
-0.7%
$8.50
$4.35
$9.32
$16.27M1.748,585 shs4,610 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IsoPlexis Co. stock logo
ISO
IsoPlexis
0.00%0.00%0.00%0.00%0.00%
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
0.00%-8.55%+87.81%-35.77%-73.56%
Precipio, Inc. stock logo
PRPO
Precipio
0.00%+0.86%+7.28%-2.69%-50.14%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
+6.51%+6.38%-1.85%+12.36%+29.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/AN/AN/AN/AN/A
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
N/AN/AN/AN/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
0.3361 of 5 stars
2.03.00.00.00.00.80.6
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.2543 of 5 stars
0.54.00.00.00.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/A
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
N/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/A$40.00545.16% Upside
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
1.00
Sell$5.00-44.07% Downside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IsoPlexis Co. stock logo
ISO
IsoPlexis
$16.76M1.81N/AN/A$1.04 per share0.73
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
$1.73M5.38N/AN/A($2.56) per share-0.11
Precipio, Inc. stock logo
PRPO
Precipio
$15.20M0.58N/AN/A$10.16 per share0.61
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$2.13M7.64N/AN/A$37.95 per share0.24

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IsoPlexis Co. stock logo
ISO
IsoPlexis
-$106M-$2.70N/AN/AN/A-632.41%-127.86%-71.41%N/A
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
-$16.08M-$1.69N/AN/A-1,050.11%N/A-1,272.67%5/14/2024 (Estimated)
Precipio, Inc. stock logo
PRPO
Precipio
-$5.85M-$4.56N/AN/A-38.51%-51.75%-37.93%5/10/2024 (Estimated)
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
-$62.01M-$34.18N/AN/A-2,905.67%-69.49%-54.15%5/9/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/AN/A
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
N/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IsoPlexis Co. stock logo
ISO
IsoPlexis
1.12
4.06
2.50
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
N/A
0.03
0.02
Precipio, Inc. stock logo
PRPO
Precipio
0.01
1.17
1.05
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/A
8.86
8.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
IsoPlexis Co. stock logo
ISO
IsoPlexis
44.91%
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
0.02%
Precipio, Inc. stock logo
PRPO
Precipio
10.45%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
43.77%

Insider Ownership

CompanyInsider Ownership
IsoPlexis Co. stock logo
ISO
IsoPlexis
6.40%
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
10.80%
Precipio, Inc. stock logo
PRPO
Precipio
10.60%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
46.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
IsoPlexis Co. stock logo
ISO
IsoPlexis
45939.76 million37.22 millionNot Optionable
Pressure BioSciences, Inc. stock logo
PBIO
Pressure BioSciences
1634.49 million30.77 millionNot Optionable
Precipio, Inc. stock logo
PRPO
Precipio
511.43 million1.28 millionOptionable
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
1021.82 million984,000No Data

PBIO, ISO, TLIS, and PRPO Headlines

SourceHeadline
Talis Biomedical Corporation (TLIS)Talis Biomedical Corporation (TLIS)
finance.yahoo.com - March 31 at 8:16 AM
Grabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical CorporationGrabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical Corporation
markets.businessinsider.com - February 16 at 8:42 PM
TLIS Feb 2024 2.500 putTLIS Feb 2024 2.500 put
finance.yahoo.com - February 15 at 2:52 AM
Peninsula diagnostics company to close Redwood City labs and offices, pursue strategic alternativesPeninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives'
bizjournals.com - November 14 at 8:38 PM
Talis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashTalis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
finanznachrichten.de - November 14 at 3:36 PM
LICY, BTAI and HROW among mid-day moversLICY, BTAI and HROW among mid-day movers
msn.com - November 14 at 3:36 PM
Talis reviewing strategic alternatives, stock rallies 35%Talis reviewing strategic alternatives, stock rallies 35%
msn.com - November 14 at 3:36 PM
Why Talis Biomedical (TLIS) Stock Is Exploding HigherWhy Talis Biomedical (TLIS) Stock Is Exploding Higher
msn.com - November 14 at 3:36 PM
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashTalis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
finance.yahoo.com - November 14 at 3:36 PM
Biomedical Engineering (BME) and Biomedical Science (BMS) ProgramsBiomedical Engineering (BME) and Biomedical Science (BMS) Programs
drexel.edu - October 23 at 1:39 AM
BTIG Maintains Talis Biomedical (TLIS) Sell RecommendationBTIG Maintains Talis Biomedical (TLIS) Sell Recommendation
msn.com - August 16 at 3:29 PM
BTIG Maintains Sell Rating for Talis Biomedical: Heres What You Need To KnowBTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To Know
markets.businessinsider.com - August 16 at 3:29 PM
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business UpdateTalis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
finance.yahoo.com - August 11 at 12:45 AM
A Preview Of Talis Biomedicals EarningsA Preview Of Talis Biomedical's Earnings
benzinga.com - August 9 at 2:02 PM
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
finance.yahoo.com - August 3 at 12:25 PM
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
finance.yahoo.com - August 2 at 12:20 PM
TLIS - Talis Biomedical CorporationTLIS - Talis Biomedical Corporation
uk.finance.yahoo.com - August 1 at 4:18 PM
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price RequirementTalis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
finance.yahoo.com - July 24 at 10:12 AM
Talis Biomedical Announces 1-for-15 Reverse Stock SplitTalis Biomedical Announces 1-for-15 Reverse Stock Split
finance.yahoo.com - July 5 at 9:12 AM
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent DirectorTalis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
finance.yahoo.com - May 23 at 1:12 PM
Talis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial ResultsTalis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
finanznachrichten.de - May 12 at 8:33 AM
Talis Biomedical reports Q1 resultsTalis Biomedical reports Q1 results
seekingalpha.com - May 11 at 8:53 PM
Talis Biomedical: Q1 Earnings InsightsTalis Biomedical: Q1 Earnings Insights
msn.com - May 11 at 8:53 PM
Talis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of ShareholdersTalis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of Shareholders
benzinga.com - May 9 at 1:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

IsoPlexis logo

IsoPlexis

NASDAQ:ISO
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Pressure BioSciences logo

Pressure BioSciences

OTCMKTS:PBIO
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.
Precipio logo

Precipio

NASDAQ:PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.
Talis Biomedical logo

Talis Biomedical

NASDAQ:TLIS
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.